CLDI
Calidi Biotherapeutics, Inc.
$0.14
0.00 (-1.39%)
At close · Jul 8
Market Cap
$2.89M
Shares
19,311,625
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$45K
FY2022
Net Income
-$19.91M
+10.1%
FY2025
Operating Margin
-51395.56%
FY2022
Diluted EPS
-$5.95
+83.3%
FY2025
Operating Cash Flow
-$21.29M
-8.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | — | — | — | $45K | — | |
| $9.9M | $9.74M | $8.88M | $13.01M | $7.26M | — | |
| $9.47M | $10.5M | $12.9M | $15.98M | $15.9M | — | |
| — | $1.65M | $1.54M | — | — | — | |
| $19.37M | $20.24M | $21.78M | $28.99M | $23.17M | $1.78M | |
| -$19.37M | -$20.24M | -$21.78M | -$28.99M | -$23.13M | -$1.78M | |
| — | — | — | — | -51395.56% | — | |
| — | -$18.59M | -$20.24M | — | — | — | |
| — | — | — | — | $1669 | $1669 | |
| $272K | $192K | -$419K | -$208K | -$2.29M | $5.17M | |
| -$19.09M | -$20.05M | -$22.2M | -$29.2M | -$25.42M | — | |
| $16K | $15K | $14K | $16K | $11K | — | |
| -$18.98M | -$19.91M | -$22.14M | -$29.22M | -$25.43M | $3.39M | |
| — | — | — | — | -56504.44% | — | |
| — | -$157K | -$66K | — | — | — | |
| -$25.01M | -$25.58M | -$23.81M | -$29.22M | $1.07M | -$28.25M | |
| -$19.02M | -$19.89M | -$22.12M | -$29.25M | -$25.44M | — | |
| USD/shares | — | -$5.95 | -$35.70 | -$207.96 | $358.80 | — |
| USD/shares | — | -$5.95 | -$35.70 | -$207.96 | $358.80 | — |
| shares | — | 4302 | 667 | 140.5K | 70.87K | — |
| shares | — | 4302 | 667 | 140.5K | 70.87K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Biotechnology median 7.68×